Maryland Lawmakers Weigh Tax Break for Drug Ads Amid Affordability Concerns

A bill currently under consideration in Annapolis could eliminate a tax break for pharmaceutical companies in Maryland, potentially generating $24 million in revenue for Medicaid and the state’s health exchange. The proposal has ignited a debate over healthcare affordability, industry rights, and the role of direct-to-consumer advertising.

Public Support for Change

A recent poll by Opinion Works revealed strong public support for the measure, with 73% of registered Maryland voters believing healthcare should be available and affordable [1]. The poll indicates a willingness among voters to support policies that redirect funds from pharmaceutical companies towards public health programs.

How the Tax Break Works

Currently, Maryland law allows drug companies to deduct the cost of prescription drug commercials as a business expense. The proposed legislation aims to eliminate this deduction, effectively increasing the tax burden on these companies [2].

Impact on Healthcare Funding

Proponents of the bill estimate it would generate approximately $24 million annually. The state plans to allocate $5 million to the Department of Health to improve Medicaid eligibility operations, addressing recent federal restrictions and staffing needs [2]. The remaining funds would be directed towards subsidies within the Maryland Affordable Care Act marketplace, helping to stabilize and lower healthcare costs [2], [3].

Personal Stories Highlight the Demand

Individuals like Bobby Laughlin, who works two jobs without health insurance, stand to benefit from increased subsidies. Laughlin faces a potential increase in his monthly premium from $70 to $500 if the state-backed subsidy expires [2]. He expressed concern about the potential for financial ruin in the event of a serious illness or accident.

Industry Opposition

Pharmaceutical companies and broadcasters are opposing the legislation, arguing it unfairly targets their industries and potentially infringes upon their First Amendment rights. Executives contend the bill is “punitive” and would uniquely penalize drug researchers and manufacturers for communicating with patients [2].

Legal Scrutiny

The Maryland Office of the Attorney General has advised that the legislation is likely defensible under the First Amendment, provided the state can demonstrate a substantial state interest [2].

Potential Coverage Losses

Nikki Highsmith, president and CEO of the Horizon Foundation, warned that without legislative action, approximately 160,000 Marylanders could lose health coverage, disproportionately impacting Black and brown communities [2].

Current Status

The bill has been heard in committees in both the Senate and the House of Representatives, but no further action has been taken as of mid-March 2026 [2], [3]. Advocates are hopeful that the poll results will provide momentum for the legislation.